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a b s t r a c t
INTRODUCTION: Colorectal adenocarcinoma and Crohn’s disease are known to be associated entities.
However, a carcinoma arising within a chronic perianal ﬁstulous tract in a patient with Crohn’s disease
is a rare complication.
PRESENTATION OF CASE: We present a case of a 40-year-old male patient with a long-standing perianal
Crohn’s disease who developed an anal mucinous adenocarcinoma within the ﬁstulous tracts.
DISCUSSION: Although, Crohn’s disease and colorectal carcinoma association is well established, few
cases have been reported where the cancer has originated within a perianal ﬁstula. Constant mucosal
regeneration occurring within a ﬁstula seems to be the predominant pathogenetic mechanism, while
immunosuppressants and anti-TNF agentsmay also contribute to themalignant transformation. Unfortu-
nately, the lack of suspicion and the inadequate physical examination or colonoscopy due to exacerbation
of the perianal symptoms could lead to delayed diagnosis; and thus, a poor prognosis.
CONCLUSION: Albeit a rare complication, clinicians should maintain a high degree of vigilance about
the possible development of adenocarcinoma in patients with long-standing perianal Crohn’s disease.
Thus, these patients should be kept under regular surveillance with examination under anaesthesia and
biopsies or curettage of the tracts.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The association between Crohn’s disease (CD) and colorectal
cancer is well established. However, carcinoma associated with
chronic ﬁstulous CD is a rare complication.We report a case of a 40-
year-old CDpatientwhodeveloped an anal adenocarcinomawithin
a long-standing perianal ﬁstulous tract and review the available
literature.
2. Presentation of case
A 40-year-old male patient with ileocolonic CD and perianal
ﬁstulising lesions, diagnosed 23 years ago, was referred to our
institution for a new ﬁnding of soft tissue within a perianal ﬁs-
tula. His past medical history included loop sigmoidostomy and
seton insertion 3 years ago for control of his perianal disease.
Three months later, due to ileus caused by terminal ileitis, he
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∗ Corresponding author. Tel.: +30 6945060768; fax: +30 2107286127.
E-mail addresses: johnpapacon@hotmail.com (I. Papaconstantinou),
dionmantzos1@yahoo.gr (D.S. Mantzos), akondi@med.uoa.gr (A. Kondi-Paﬁti),
ikoutroubakis@gmail.com (I.E. Koutroubakis).
underwent emergency right colectomy. At the same time, the
loop sigmoidostomy was converted to end colostomy with clo-
sure of the peripheral stump; since, the perianal disease was
still uncontrollable. At this time, taking into account the benign
nature of the disease, as well as patient’s age, it was decided to
give to the patient a second chance to keep his sphincter mecha-
nism rather than to perform an abdominoperineal resection. The
patient had received in the past, either in conjunction or conse-
quently, corticosteroids, antibiotics (metronidazole, ciproﬂoxacin),
immunosuppressants (azathioprine, methotrexate) and anti-TNF
agents (inﬂiximab) for the control of the frequent ﬂare-ups. On
referral, he was on adalimumab and mercaptopurine. Physical
examination revealed mild perianal inﬂammation with muco-
purulent discharge from two sore-like ﬁstulous oriﬁces, located
at 7 and 11 o’clock in supine position (Fig. 1). Pelvic magnetic
resonance imaging (MRI) demonstrated pathological tissue devel-
opment within one ﬁstulous tract (Fig. 2) suggesting a mucinous
cancer arising within the ﬁstula. The rectosigmoidoscopy depicted
mild lesions compatible with moderately active CD, without any
other sign of obvious malignancy. Mucosal biopsies were obtained
from the lesions and the underlying ﬁstulous tracts; granulo-
matous tissue inﬁltrated by mucus-producing adenocarcinoma
was found on pathology. Staging with computed tomography did
not reveal any metastatic disease. Thus, the patient underwent
http://dx.doi.org/10.1016/j.ijscr.2015.04.013
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Fistulous oriﬁces at 7 and 11 o’clock.
abdominoperineal resection, where a 37 cm segment of colon with
the mesorectum, anal canal of 7 cm and the corresponding overly-
ing soft tissue of the perineum was resected. On histopathology,
a T4N1 moderately/poorly differentiated mucinous adenocarci-
noma was detected (Fig. 3). According to the referrer, his last
physical examination, six months prior to admission, was unre-
markable. Unfortunately, threemonths postoperatively the patient
developed multiple bone metastases and he is currently receiving
chemotherapy.
3. Discussion
Up to 43% of CDpatientswill develop perianal ﬁstulising disease
[1]. The development of carcinomawithin a chronic perianal ﬁstula
is a rare complication of CD, ﬁrst reported by Lightdale et al. in 1975
[2]. Iesalnieks et al. has reported 65 cases with anorectal cancer
associated with perianal ﬁstulae in patients with CD [3] with an
estimated incidence of 0.3–0.7% [4].
The pathogenesis has not yet been fully elucidated; Traube at al.
suggested that the environment of constant mucosal regeneration
occurringwithin a ﬁstulamay cause dysplastic changes,whichmay
ultimately lead to adenocarcinoma [5]. On the contrary, Church
Fig. 2. MRI of adenocarcinoma developingwithin ﬁstulous tracts (high signal inten-
sity on T2-weighted image).
Fig. 3. Histological section of perianal ﬁstulous tract inﬁltrated by
moderately–poorly differentiated mucus – producing adenocarcinoma
(haematoxylin− eosin×100).
et al. supported that a ﬁstula formation may be a result of the can-
cer itself [6]. In the present case, the pre-existence of long-standing
ﬁstulae renders the latter improbable. It has been suggested that
immunosuppressants and anti-TNF agents may contribute to the
malignant transformation [7]. In a recent article, Osterman et al.
supported that patients treated with combination of adalimumab
and immunomodulators were more likely to develop cancer com-
pared both to general population and patients with adalimumab
monotherapy [8]. This plausiblepathogeneticmechanismmayhold
true in the present case, where the patient had been treated with
anti-TNFand immunomodulators for approximately tenyearsprior
to the diagnosis of cancer.
Patients with long-standing CD, diagnosed before thirty years
of age and with faecal diversion are at greater risk for the devel-
opment of carcinoma arising in association with a perianal ﬁstula
[9]. Unfortunately, the majority of these patients have poor prog-
nosis due to the advanced disease stage at diagnosis. Similarities
between benign deterioration of the perianal symptoms and de
novo development of cancer, as well as the lack of a high degree
of suspicion for this rare complication may be responsible for the
delay of diagnosis. Furthermore, the exacerbation of the symptoms
makes physical examination or colonoscopy cumbersome to occur.
A complex, long-standing ﬁstula requires thorough examination of
the rectum and the perianal area under anaesthesia followed by
biopsies and/or curettage of the ﬁstulous tracts. It follows, those
patients with chronic perianal ﬁstulising CD should be kept under
a regular and careful surveillance. Ogawa et al. have suggested that
a patient should undergo surveillance for carcinoma after seven
years of perianal disease [4].
The gold standard treatment of ﬁstulae-associated anal adeno-
carcinoma in patients with CD is abdominoperineal resection. In a
recent article, Gaertner et al. reported that all patientswithperianal
adenocarcinomawho had undergone neoadjuvant chemoradiation
therapy followed by abdominoperineal resection had a complete
response [10]. Thepotential beneﬁtsof this kindof therapyhavenot
yet been established; and therefore, in our patient we proceeded
only to surgical treatment.
4. Conclusion
Clinicianswhomanage patients with long-standing perianal CD
should maintain high level of suspicion for adenocarcinoma devel-
opment on the setting of perianal ﬁstulising CD. A chronic, complex
ﬁstulous diseasemay conceal a tumour and the examination under
anaesthesia with biopsies and/or curettage of the ﬁstulous tracts
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may be warranted. Therefore, all patients suffering from chronic
perianal CD should be kept under regular surveillance.
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